Pharmicell Co Ltd

005690

Company Profile

  • Business description

    Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

  • Contact

    12F Chungho B/D
    3-2 Nonhyun-dong Gangnam-gu
    Seoul135-010
    KOR

    T: +82 234960114

    http://www.pharmicell.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    161

Stocks News & Analysis

stocks

Investors punish this ASX player after acquisition

We think the floundering stock price is not reflective of underlying asset value.
stocks

Revenue growth on track for undervalued ASX healthcare stock

Near-term cost growth does not change our long-term view.
stocks

Sales shine but broader macro outlook darkens for this ASX share

US stores are struggling, but our investment thesis hinges on the Australian rollout.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,155.8034.000.37%
CAC 408,259.6013.810.17%
DAX 4023,803.953.04-0.01%
Dow JONES (US)47,916.57269.23-0.56%
FTSE 10010,600.532.95-0.03%
HKSE25,893.54141.140.55%
NASDAQ22,902.8980.480.35%
Nikkei 22556,924.111,028.791.84%
NZX 50 Index13,181.4492.37-0.70%
S&P 5006,816.897.77-0.11%
S&P/ASX 2008,960.6036.200.41%
SSE Composite Index3,986.2220.050.51%

Market Movers